While our review has not provided clear evidence that FAAH or MAGL inhibitors would be useful for treating obesity, it will be worth noting whether there are any weight- or obesity-related effects observed in FAAH and/or MAGL inhibitor trials. Here, MGLL is linked to obesity due to melanocortin 4 receptor deficiency.